/

MBIO

Mustang Bio, Inc.Closed

0.3768−0.04 −8.63%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 0.3814 +1.22%

Open

0.3940

Prev close

0.4124

Day range

0.37480.3958

52-week range

0.37481.69

Volume

29.69K0.99×

Mkt cap

2.86M

P/E ttm

—

Fwd P/E

-1.08

EPS ttm

-0.4400

Div yield

0.00%

Earnings

—

From 52w high

−77.70%

Price Chart

Yahoo Finance · delayed

MBIOOct 13, 2026O 0.3940H 0.3960L 0.3750C 0.3770−0.0350 (−8.50%)Vol 30.00K

SMA 500.5275
SMA 2000.7321

1Y change −76.87% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

MBIO Mustang Bio, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −18.04%
1 month: −25.64%
3 months: −43.05%
6 months: −49.73%
Year to date: −61.57%
1 year: −76.87%

Valuation & ownership

Market cap: 2.86M
Enterprise value: −12.30M
P/E (ttm): —
Forward P/E: -1.08
PEG ratio: —
Price / book: 0.38
Price / sales (ttm): —
EV / EBITDA: 3.51
EPS (ttm): -0.4400
EPS (forward): -0.3500
Beta (5y monthly): 2.09
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 6.73M
Float: 6.19M
Short % of float: 0.78%
Short ratio (days): 1.96
Held by insiders: 8.02%
Held by institutions: 9.93%
Avg volume (3m): 30.07K
50-day average: 0.5315
200-day average: 0.7355
52-week change: −76.87%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): oversold 23.7
vs 50-day SMA: −28.53%
vs 200-day SMA: −48.50%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 8.15%
Realised vol (20d, ann.): 65.3%
From 52-week high: −77.69%
From 52-week low: +0.53%

ANR

Analyst Consensus

No analyst coverage for this instrument.

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): —
Revenue growth (yoy): —
Earnings growth (yoy): —
Gross margin: 0.00%
Operating margin: 0.00%
Profit margin: 0.00%

DES

About Mustang Bio, Inc.

Yahoo Finance profile

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children's hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Employees: 4
Headquarters: Waltham, MA, United States
Website: mustangbio.com
Officers: Mr. Michael S. Weiss Esq., J.D. Executive Chairman
Dr. Manuel Litchman M.D. President, CEO, Interim CFO & Director
Mr. Peter Carney Controller & Interim Chief Accounting Officer
Mr. Greg Furrow M.S.

SEAS

Seasonality · MBIO

2017–2026 · monthly returns

Strongest month Jun +10.08%Weakest month Feb −17.06%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-1.6	4.7	-27.9	1.8	-9.6	4.8	-18.8	-5.6	-13.9	-18.6			−61.6%
2025	-51.2	-53.7	-37.5	-12.8	20.2	-27.1	60.2	-1.3	0.7	-4.6	-2.8	-30.4	−88.9%
2024	6.7	-6.3	-23.0	-76.2	-19.0	135.3	-29.4	-15.9	-16.4	19.1	-28.6	-11.5	−86.9%
2023	71.6	-18.9	-33.3	-23.0	50.7	-2.8	-16.3	-39.0	-34.7	-20.8	-12.2	-6.3	−77.2%
2022	-28.9	-26.4	16.2	-26.2	-13.4	-9.3	-0.9	4.8	-22.9	15.6	-6.8	-21.8	−76.2%
2021	10.2	-15.3	-5.9	-2.7	3.7	-0.9	-13.0	5.2	-11.5	-16.7	-9.8	-17.8	−56.1%
2020	-10.0	-20.4	-8.2	3.0	35.1	-14.7	-3.1	6.2	-3.7	-15.4	38.8	2.3	−7.2%
2019	26.5	11.0	-17.4	21.7	-17.3	7.3	-17.1	29.2	-17.3	-18.7	19.6	28.7	+38.8%
2018	-0.4	-6.5	-2.0	-17.8	-17.5	-7.1	-0.6	1.0	-14.0	-33.1	0.8	-26.7	−75.5%
2017									-8.8	-0.8	-17.9	24.2	−7.6%

INSD

Insider Activity · MBIO

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Jan 1, 2026	Fortress Biotech, Inc.Beneficial Owner of more than 10% of a Class of Security	Stock Award(Grant) at price 0.00 per share.	278.4K	—
Dec 29, 2025	Herskowitz NeilDirector	Sale at price 0.96 per share.	247	$238
Dec 29, 2025	Chill Adam JDirector	Sale at price 0.95 per share.	4	$4
Dec 29, 2025	Jin DavidDirector	Purchase at price 0.96 per share.	247	$238
Sep 28, 2025	Fortress Biotech, Inc.Beneficial Owner of more than 10% of a Class of Security	Stock Award(Grant) at price 0.00 per share.	59.3K	—
Mar 30, 2025	Fortress Biotech, Inc.Beneficial Owner of more than 10% of a Class of Security	Stock Award(Grant) at price 0.00 per share.	67.8K	—

MBIO

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

MBIO

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Mustang Bio, Inc.

Seasonality · MBIO

Insider Activity · MBIO

Congress Trades · MBIO

Investors Holding MBIO

Investors Holding MBIO

Congress Trades · MBIO

Insider Activity · MBIO

Seasonality · MBIO

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Mustang Bio, Inc.

Earnings & Dividends

News